Thierry Lamy

12.1k total citations
177 papers, 6.4k citations indexed

About

Thierry Lamy is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Thierry Lamy has authored 177 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Pathology and Forensic Medicine, 74 papers in Genetics and 62 papers in Oncology. Recurrent topics in Thierry Lamy's work include Lymphoma Diagnosis and Treatment (86 papers), Chronic Lymphocytic Leukemia Research (60 papers) and Immune Cell Function and Interaction (28 papers). Thierry Lamy is often cited by papers focused on Lymphoma Diagnosis and Treatment (86 papers), Chronic Lymphocytic Leukemia Research (60 papers) and Immune Cell Function and Interaction (28 papers). Thierry Lamy collaborates with scholars based in France, United States and United Kingdom. Thierry Lamy's co-authors include Thomas P. Loughran, Thierry Fest, Aline Moignet, Karin Tarte, Céline Pangault, Gilles Salles, Patricia Amé-Thomas, Bernard Drénou, Nöel Milpied and Jin Hong Liu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Thierry Lamy

173 papers receiving 6.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Thierry Lamy 2.6k 2.6k 2.3k 2.1k 1.9k 177 6.4k
Michinori Ogura 2.2k 0.8× 3.2k 1.3× 3.0k 1.3× 1.8k 0.9× 1.5k 0.8× 223 7.3k
Corrado Tarella 1.3k 0.5× 2.8k 1.1× 2.8k 1.2× 1.5k 0.7× 2.5k 1.3× 213 6.2k
Lorenz Trümper 1.6k 0.6× 3.9k 1.5× 3.3k 1.4× 2.1k 1.0× 1.0k 0.5× 203 7.5k
Lisa M. Rimsza 1.2k 0.5× 3.5k 1.4× 2.6k 1.2× 1.6k 0.7× 1.2k 0.6× 199 6.2k
Alessandro Pileri 1.9k 0.7× 2.4k 0.9× 3.2k 1.4× 1.6k 0.7× 4.1k 2.2× 335 8.2k
Eckhart Weidmann 1.3k 0.5× 2.1k 0.8× 2.0k 0.9× 1.3k 0.6× 770 0.4× 111 5.0k
Sven de Vos 1.3k 0.5× 3.9k 1.5× 3.6k 1.6× 2.6k 1.2× 1.2k 0.6× 192 7.6k
Richard Rosenquist 2.5k 1.0× 3.7k 1.4× 1.6k 0.7× 4.3k 2.1× 994 0.5× 255 7.7k
Lubomir Sokol 1.4k 0.5× 2.0k 0.8× 1.8k 0.8× 1.4k 0.7× 1.3k 0.7× 269 5.3k
Mark Kirschbaum 1.7k 0.6× 1.1k 0.4× 2.1k 0.9× 887 0.4× 3.2k 1.7× 66 6.2k

Countries citing papers authored by Thierry Lamy

Since Specialization
Citations

This map shows the geographic impact of Thierry Lamy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Lamy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Lamy more than expected).

Fields of papers citing papers by Thierry Lamy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thierry Lamy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Lamy. The network helps show where Thierry Lamy may publish in the future.

Co-authorship network of co-authors of Thierry Lamy

This figure shows the co-authorship network connecting the top 25 collaborators of Thierry Lamy. A scholar is included among the top collaborators of Thierry Lamy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thierry Lamy. Thierry Lamy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marchi, Enrica, Tapan M. Kadia, Christina Poh, et al.. (2025). Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia. Blood. 146(Supplement 1). 777–777.
2.
Marchand, Tony, Cédric Pastoret, Gandhi Damaj, et al.. (2024). Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia. British Journal of Haematology. 205(3). 915–923. 6 indexed citations
3.
4.
Desmots, Fabienne, Delphine Rossille, Mikaël Roussel, et al.. (2023). The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity. Clinical Cancer Research. 29(12). 2280–2290. 1 indexed citations
5.
Baptiste, Amandine, Lisa Belin, Pascale Ghillani‐Dalbin, et al.. (2022). Immunochemotherapy versus rituximab in anti‐myelin‐associated glycoprotein neuropathy: A report of 64 patients. British Journal of Haematology. 198(2). 298–306. 4 indexed citations
6.
Pastoret, Cédric, Fabienne Desmots, Simon Le Gallou, et al.. (2021). Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells. Blood. 137(23). 3237–3250. 35 indexed citations
7.
8.
Pangault, Céline, Patricia Amé-Thomas, Delphine Rossille, et al.. (2020). Integrative Analysis of Cell Crosstalk within Follicular Lymphoma Cell Niche: Towards a Definition of the FL Supportive Synapse. Cancers. 12(10). 2865–2865. 14 indexed citations
9.
Humbert, Marc, Francis LeBlanc, Renato Zambello, et al.. (2020). Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. CHEST Journal. 158(6). 2602–2609. 7 indexed citations
10.
Desmots, Fabienne, Mikaël Roussel, Céline Pangault, et al.. (2018). Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma. Clinical Cancer Research. 25(2). 735–746. 19 indexed citations
11.
Arcaini, Luca, Thierry Lamy, Jan Walewski, et al.. (2017). Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. British Journal of Haematology. 180(2). 224–235. 9 indexed citations
12.
Azzaoui, Imane, Fabrice Uhel, Delphine Rossille, et al.. (2016). T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood. 128(8). 1081–1092. 123 indexed citations
13.
Amin, Rada, Frédéric Mourcin, Fabrice Uhel, et al.. (2015). DC-SIGN–expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood. 126(16). 1911–1920. 92 indexed citations
14.
Gallouët, Anne-Sophie, Marion Travert, Laurence Bresson‐Bepoldin, et al.. (2014). COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis. Clinical Cancer Research. 20(10). 2663–2673. 35 indexed citations
15.
16.
Avet‐Loiseau, Hervé, Florent Malard, L. Campion, et al.. (2010). Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. Blood. 117(6). 2009–2011. 92 indexed citations
17.
Hajjami, Hélène Maby–El, Patricia Amé-Thomas, Céline Pangault, et al.. (2009). Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase. Cancer Research. 69(7). 3228–3237. 65 indexed citations
18.
Travert, Marion, Patricia Amé-Thomas, Céline Pangault, et al.. (2008). CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-κB Activation and Up-Regulation of c-FLIP and Bcl-xL. The Journal of Immunology. 181(2). 1001–1011. 71 indexed citations
19.
Amé-Thomas, Patricia, Hélène Maby–El Hajjami, Céline Monvoisin, et al.. (2006). Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood. 109(2). 693–702. 177 indexed citations
20.
Lamy, Thierry, M. Hamidou, & Thomas P. Loughran. (1999). Spectre des proliférations LGL et nouveaux concepts physiopathogéniques. Hématologie. 5(4). 300–308. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michinori Ogura Breakdown of academic impact, for papers by Corrado Tarella Breakdown of academic impact, for papers by Lorenz Trümper Breakdown of academic impact, for papers by Lisa M. Rimsza Breakdown of academic impact, for papers by Alessandro Pileri Breakdown of academic impact, for papers by Eckhart Weidmann Breakdown of academic impact, for papers by Sven de Vos Breakdown of academic impact, for papers by Richard Rosenquist Breakdown of academic impact, for papers by Lubomir Sokol Breakdown of academic impact, for papers by Mark Kirschbaum
Rankless by CCL
2026